GoodRx, a resource for healthcare savings and information, is working with Sanofi, a company that specializes in diabetes care, to offer people living with diabetes access to Lantus (insulin glargine ...

Sanofi cuts U.S. list price of Lantus ®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance Paris, March 16, 2023. Sanofi ...

Sanofi top-lined positive late-stage clinical data today from a new basal insulin designed to help the French drugmaker defend its position in this fast-growing segment of diabetes treatment. In two ...

GoodRx is teaming up with Sanofi to offer consumers access to its most prescribed insulin, Lantus, for $35 at thousands of pharmacies nationwide. All Americans with a valid prescription, regardless of ...

Sanofi’s Lantus, its most commonly prescribed insulin, will sell for $35 a month through GoodRx Holdings Inc. in a deal that signals the drug-discount site’s growing business with large pharma ...

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (NASDAQ: GDRX), a leading resource for healthcare savings and information, today announced it is working with Sanofi (NASDAQ: SNY), a global leader in ...

In a March 16 press release, the French drugmaker, which currently has its U.S. headquarters in Bridgewater, said the changes are slated to go into effect Jan. 1, 2024. Along with cutting down the ...

LONDON, June 29 (Reuters) - Sanofi-Aventis's diabetes drug Lantus may increase the risk of cancer, according to new but inconclusive studies from experts around Europe. Shares in the French drugmaker ...

Sanofi SNY announced up to a 78% cut in the list price of its most popular insulin, Lantus, following the likes of rival Novo Nordisk NVO and Eli Lilly LLY. Similar to Lilly, Sanofi also said it is ...

(Reuters) - Sanofi SA, whose top-selling Lantus helps diabetics control blood sugar levels, has filed a lawsuit accusing Eli Lilly and Co of infringing seven patents related to insulin and devices ...

Sanofi will continue to provide different programs to ensure access and affordability to patients depending on their coverage situations and will continue to monitor policy and market changes. Our ...